- Stocks
- Pharma & Healthcare
- Adline Chem Lab
Adline Chem Lab share price
NSE: ADLINEPharma & HealthcareDrug Manufacturers - Specialty & Generic
Adline Chem Lab at a glance
With a market capitalisation of ₹8 Cr, it ranks 3968th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY25. Promoters held 25.85% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹8 CrRank 3968 on NSE
- Price to book
- -5.2×FY25
- EPS (TTM)
- −₹0.20to Q4 FY26
- ROE
- 0.0%FY25
- ROCE
- −74.8%FY25
- Debt to equity
- -1FY25
- Net profit margin
- 0.0%FY25
- Book value / share
- −₹2.55FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Adline Chem Lab quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | −₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit YoY | — | — | — | — | — | — | — | −142.9% |
| Net margin | — | — | — | — | — | — | — | — |
| EPS | −₹0.17 | −₹0.02 | −₹0.02 | ₹0.04 | −₹0.01 | −₹0.01 | −₹0.01 | −₹0.17 |
Adline Chem Lab financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹7 Cr | ₹6 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | −₹4 Cr | −₹1 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit | −₹4 Cr | −₹1 Cr | ₹1 Cr | −₹4 Cr | −₹0 Cr | −₹0 Cr |
| EPS (₹) | −₹6.45 | −₹2.19 | ₹1.23 | −₹7.24 | −₹0.25 | −₹0.21 |
| Cash from operations | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Shareholders' equity | ₹3 Cr | ₹2 Cr | ₹3 Cr | −₹2 Cr | −₹2 Cr | −₹1 Cr |
Adline Chem Lab shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 29.61% | 29.61% | 25.85% | 25.85% | 25.85% |
| Non-institutions | 70.39% | 70.39% | 74.15% | 74.15% | 74.15% |
Adline Chem Lab vs peers
The listed Pharma & Healthcare companies nearest to Adline Chem Lab by market capitalisation.
Ask anything about Adline Chem Lab
Pivot answers on the live chart with evidence you can check, and tests strategies against ADLINE's own history. Try: “Why has ADLINE moved over the last three months?” · “Backtest a 50-day moving-average crossover on ADLINE over five years” · “Compare ADLINE with CTLLAB on margins and valuation”
Frequently asked questions about Adline Chem Lab
What is the market cap of Adline Chem Lab?
Adline Chem Lab's market capitalisation is ₹8 Cr (₹8 Cr) at the 22 Oct 2026 close, ranking 3968th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Adline Chem Lab?
Return on equity was 0.0% in FY25 and return on capital employed was −74.8% in FY25 (standalone figures).
Is Adline Chem Lab a debt-free company?
Adline Chem Lab is close to debt-free: its debt-to-equity ratio was -1 in FY25.
What is the shareholding pattern of Adline Chem Lab?
As of 30 Jun 2026: promoters 25.85%, non-institutions 74.15%.
Who are Adline Chem Lab's competitors?
The listed Pharma & Healthcare companies closest to Adline Chem Lab by market cap are Clinitech Labor, Genomic Valley, Trinity League, Unjha Formula, Dr Lalchandani and Vivanza Bio.
Is Adline Chem Lab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Adline Chem Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ADLINE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text